Novo Nordisk A/S
NOVO-B
Rankning i aktier
#108
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Aktiekurs
$39.74
Marknadsvärde
$175.38B
Förändring (1 dag)
1.28%
Förändring (1 år)
-25.58%
Land
DK
Handel Novo Nordisk A/S (NOVO-B)
Kategori
Healthcare
P/B-tal för Novo Nordisk A/S (NOVO-B)
P/B-tal per October 2026 TTM: 5.30
Enligt Novo Nordisk A/S senaste finansiella rapporter och aktiekurs är det aktuella P/B-talet (TTM) 5.30. I slutet av 2024 hade företaget ett P/B-tal på 19.38.
Historik för P/B-tal för Novo Nordisk A/S från 2001 till 2026
P/B-tal vid årets slut
| År | P/B-tal | Ändra |
|---|---|---|
| 2026 (TTM) | 5.30 | -28.89% |
| 2025 | 7.45 | -61.56% |
| 2024 | 19.38 | -34.02% |
| 2023 | 29.37 | 15.39% |
| 2022 | 25.45 | 6.65% |
| 2021 | 23.87 | 51.77% |
| 2020 | 15.72 | -1.35% |
| 2019 | 15.94 | 12.22% |
| 2018 | 14.20 | -14.34% |
| 2017 | 16.58 | 16.48% |
| 2016 | 14.23 | -34.97% |
| 2015 | 21.89 | 29.23% |
| 2014 | 16.94 | 35.36% |
| 2013 | 12.51 | -0.67% |
| 2012 | 12.60 | 26.42% |
| 2011 | 9.97 | 0.88% |
| 2010 | 9.88 | 77.44% |
| 2009 | 5.57 | 9.91% |
| 2008 | 5.07 | -20.41% |
| 2007 | 6.36 | 25.26% |
| 2006 | 5.08 | 20.40% |
| 2005 | 4.22 | 11.39% |
| 2004 | 3.79 | 16.59% |
| 2003 | 3.25 | 4.96% |
| 2002 | 3.10 | -47.14% |
| 2001 | 5.86 | 0.00% |
P/B-tal för liknande företag eller konkurrenter
| Företag | P/B-tal | Skillnad i P/B-tal | Land |
|---|---|---|---|
| 34.4295 | 549.86% |
US
|
|
| 7.8748 | 48.64% |
US
|
|
| -84.9599 | -1,703.62% |
US
|
|
| 9.0001 | 69.88% |
US
|
|
| 9.7057 | 83.20% |
CH
|
